Safety, Tolerability, and Immunogenicity of an mRNA COVID-19 Vaccine Incorporating the Novel 5′ Cap Analogue SmartCap® SC101: Results from a First-in-Human Phase I Dose-Escalation Study
Background/Objectives: Messenger RNA (mRNA) vaccines have enabled rapid vaccine development and have become an important platform for pandemic preparedness; however, clinical evaluation of alternative co-transcriptional 5′ cap technologies remains limited. Here, we report the first-in-human safety, tolerability, and im...